Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, PR China.
Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, PR China.
Diabetes Res Clin Pract. 2022 Mar;185:109776. doi: 10.1016/j.diabres.2022.109776. Epub 2022 Feb 9.
In diet-induced arterial atherosclerosis, increased KCa3.1 channel was associated with atherosclerotic plaque progression and instability. Macrophages are involved in the formation of atherosclerotic plaques, and the release of inflammatory cytokines and oxygen free radicals promotes plaque progression. However, whether the macrophage KCa3.1 channel facilitates diabetes-accelerated atherosclerosis is still unclear. This study investigated atherosclerotic plaque in ApoE mice regulated by the KCa3.1 channel.
In vivo, blocking KCa3.1channel inhibit the development of the atherosclerotic lesion in diabetic ApoE mice fed with a high-fat diet. In vitro, upregulation of KCa3.1 channel level occurred in RAW264.7 cells treated with HG plus ox-LDL in a time-dependent manner. Blocking KCa3.1 significantly reduced the uptake of ox-LDL in mice peritoneal macrophages. Further studies indicated the KCa3.1 siRNA and TRAM-34 (KCa3.1 inhibitor) attenuated the scavenger receptor CD36 expression via inhibiting STAT3 phosphorylation.
Blockade of macrophage KCa3.1 channel inhibit cellular oxidized low-density lipoprotein accumulation and decrease proinflammation factors expression via STAT3/CD36 axis. This study provided a novel therapeutic target to reduce the risk of atherosclerosis development in diabetic patients.
在饮食诱导的动脉粥样硬化中,KCa3.1 通道的增加与动脉粥样硬化斑块的进展和不稳定性有关。巨噬细胞参与动脉粥样硬化斑块的形成,炎症细胞因子和氧自由基的释放促进斑块进展。然而,巨噬细胞 KCa3.1 通道是否促进糖尿病加速的动脉粥样硬化尚不清楚。本研究探讨了 KCa3.1 通道调节的 ApoE 小鼠的动脉粥样硬化斑块。
在体内,阻断 KCa3.1 通道可抑制高脂饮食喂养的糖尿病 ApoE 小鼠动脉粥样硬化病变的发展。在体外,高糖加 ox-LDL 处理 RAW264.7 细胞时,KCa3.1 通道水平呈时间依赖性上调。阻断 KCa3.1 可显著减少小鼠腹腔巨噬细胞对 ox-LDL 的摄取。进一步的研究表明,KCa3.1 siRNA 和 TRAM-34(KCa3.1 抑制剂)通过抑制 STAT3 磷酸化来减弱清道夫受体 CD36 的表达。
阻断巨噬细胞 KCa3.1 通道可通过 STAT3/CD36 轴抑制细胞氧化型低密度脂蛋白的积累和促炎因子的表达。本研究为降低糖尿病患者动脉粥样硬化发展的风险提供了一个新的治疗靶点。